
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ASND | NASDAQ | USD | Real-time | |
A71 | Frankfurt | EUR | Delayed | |
A71 | TradeGate | EUR | Delayed |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Jan Moller Mikkelsen | 61 | 2007 | President, CEO, Member of Executive Board & Executive Director |
Albert Cha | 49 | 2014 | Independent Chairman |
William Carl Fairey | - | 2022 | Director |
Lisa Bright Morrison | 55 | 2017 | Independent Director |
Lars Holtug | 65 | 2018 | Independent Director |
William Carl Fairey | 59 | 2022 | Independent Director |
Siham Imani | 45 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review